Skip to main content
Top
Published in: BMC Cancer 1/2023

Open Access 01-12-2023 | Breast Cancer | Research

Multidimensional analysis to elucidate the possible mechanism of bone metastasis in breast cancer

Authors: Kang Yao, Zhu Xiaojun, Zhao Tingxiao, Liao Shiyao, Ji Lichen, Zhang Wei, Li Yanlei, Tian Jinlong, Ding Xiaoyan, Zhang Jun, Bi Qing, Lv Jun

Published in: BMC Cancer | Issue 1/2023

Login to get access

Abstract

Background

Breast cancer (BC) patients tend to suffer from distant metastasis, especially bone metastasis.

Methods

All the analysis based on open-accessed data was performed in R software, dependent on multiple algorithms and packages. The RNA levels of specific genes were detected using quantitative Real-time PCR as a method of detecting the RNA levels. To assess the ability of BC cells to proliferate, we utilized the CCK8 test, colony formation, and the 5-Ethynyl-20-deoxyuridine assay. BC cells were evaluated for invasion and migration by using Transwell assays and wound healing assays.

Results

In our study, we identified the molecules involved in BC bone metastasis based on the data from multiple BC cohorts. Then, we comprehensively investigated the effect pattern and underlying biological role of these molecules. We found that in the identified molecules, the EMP1, ACKR3, ITGA10, MMP13, COL11A1, and THY1 were significantly correlated with patient prognosis and mainly expressed in CAFs. Therefore, we explored the CAFs in the BC microenvironment. Results showed that CAFs could activate multiple carcinogenic pathways and most of these pathways play an important role in cancer metastasis. Meanwhile, we noticed the interaction between CAFs and malignant, endothelial, and M2 macrophage cells. Moreover, we found that CAFs could induce the remodeling of the BC microenvironment and promote the malignant behavior of BC cells. Then, we identified MMP13 for further analysis. It was found that MMP13 can enhance the malignant phenotype of BC cells. Meanwhile, biological enrichment and immune infiltration analysis were conducted to present the effect pattern of MMP13 in BC.

Conclusions

Our result can improve the understanding of researchers on the underlying mechanisms of BC bone metastasis.
Literature
1.
go back to reference Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. Cancer J Clin. 2022;72(1):7–33 PubMed PMID: 35020204. Epub 2022/01/13. eng. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. Cancer J Clin. 2022;72(1):7–33 PubMed PMID: 35020204. Epub 2022/01/13. eng.
2.
go back to reference Nagarajan D, McArdle SEB. Immune Landscape of breast cancers. Biomedicines. 2018;6(1):20. PubMed PMID: 29439457. Pubmed Central PMCID: PMC5874677. Epub 2018/02/15. eng. Nagarajan D, McArdle SEB. Immune Landscape of breast cancers. Biomedicines. 2018;6(1):20. PubMed PMID: 29439457. Pubmed Central PMCID: PMC5874677. Epub 2018/02/15. eng.
3.
go back to reference Makhoul I, Atiq M, Alwbari A, Kieber-Emmons T. Breast Cancer Immunotherapy: an update. Breast cancer: Basic and Clinical Research. 2018;12:1178223418774802 (PubMed PMID: 29899661. Pubmed Central PMCID: PMC5985550. Epub 2018/06/15. eng).PubMed Makhoul I, Atiq M, Alwbari A, Kieber-Emmons T. Breast Cancer Immunotherapy: an update. Breast cancer: Basic and Clinical Research. 2018;12:1178223418774802 (PubMed PMID: 29899661. Pubmed Central PMCID: PMC5985550. Epub 2018/06/15. eng).PubMed
4.
go back to reference Zhu X, Ying J, Wang F, Wang J, Yang H. Estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 status in invasive Breast cancer: a 3,198 cases study at National Cancer Center, China. Breast Cancer Res Treat. 2014;147(3):551–5 (PubMed PMID: 25234844. Epub 2014/09/23. eng).PubMed Zhu X, Ying J, Wang F, Wang J, Yang H. Estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 status in invasive Breast cancer: a 3,198 cases study at National Cancer Center, China. Breast Cancer Res Treat. 2014;147(3):551–5 (PubMed PMID: 25234844. Epub 2014/09/23. eng).PubMed
5.
go back to reference Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y, et al. Identification of human triple-negative Breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Investig. 2011;121(7):2750–67 (PubMed PMID: 21633166. Pubmed Central PMCID: PMC3127435. Epub 2011/06/03. eng).PubMedPubMedCentral Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y, et al. Identification of human triple-negative Breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Investig. 2011;121(7):2750–67 (PubMed PMID: 21633166. Pubmed Central PMCID: PMC3127435. Epub 2011/06/03. eng).PubMedPubMedCentral
6.
go back to reference Chen X, Xu D, Li X, Zhang J, Xu W, Hou J, et al. Latest overview of the cyclin-dependent kinases 4/6 inhibitors in Breast Cancer: the past, the Present and the future. J Cancer. 2019;10(26):6608–17 (PubMed PMID: 31777590. Pubmed Central PMCID: PMC6856891. Epub 2019/11/30. eng).PubMedPubMedCentral Chen X, Xu D, Li X, Zhang J, Xu W, Hou J, et al. Latest overview of the cyclin-dependent kinases 4/6 inhibitors in Breast Cancer: the past, the Present and the future. J Cancer. 2019;10(26):6608–17 (PubMed PMID: 31777590. Pubmed Central PMCID: PMC6856891. Epub 2019/11/30. eng).PubMedPubMedCentral
7.
go back to reference Takada M, Toi M. Neoadjuvant treatment for HER2-positive Breast cancer. Chin Clin Oncol. 2020;9(3):32 (PubMed PMID: 32527117. Epub 2020/06/13. eng).PubMed Takada M, Toi M. Neoadjuvant treatment for HER2-positive Breast cancer. Chin Clin Oncol. 2020;9(3):32 (PubMed PMID: 32527117. Epub 2020/06/13. eng).PubMed
8.
go back to reference Liedtke C, Mazouni C, Hess KR, André F, Tordai A, Mejia JA, et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative Breast cancer. J Clin Oncology: Official J Am Soc Clin Oncol. 2008;26(8):1275–81 (PubMed PMID: 18250347. Epub 2008/02/06. eng). Liedtke C, Mazouni C, Hess KR, André F, Tordai A, Mejia JA, et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative Breast cancer. J Clin Oncology: Official J Am Soc Clin Oncol. 2008;26(8):1275–81 (PubMed PMID: 18250347. Epub 2008/02/06. eng).
9.
go back to reference DeSantis CE, Ma J, Gaudet MM, Newman LA, Miller KD, Goding Sauer A, et al. Breast cancer statistics, 2019. Cancer J Clin. 2019;69(6):438–51 (PubMed PMID: 31577379. Epub 2019/10/03. eng). DeSantis CE, Ma J, Gaudet MM, Newman LA, Miller KD, Goding Sauer A, et al. Breast cancer statistics, 2019. Cancer J Clin. 2019;69(6):438–51 (PubMed PMID: 31577379. Epub 2019/10/03. eng).
10.
go back to reference Ginsburg O, Bray F, Coleman MP, Vanderpuye V, Eniu A, Kotha SR, et al. The global burden of women’s cancers: a grand challenge in global health. Lancet (London England). 2017;389(10071):847–60 (PubMed PMID: 27814965. Pubmed Central PMCID: PMC6191029. Epub 2016/11/07. eng).PubMed Ginsburg O, Bray F, Coleman MP, Vanderpuye V, Eniu A, Kotha SR, et al. The global burden of women’s cancers: a grand challenge in global health. Lancet (London England). 2017;389(10071):847–60 (PubMed PMID: 27814965. Pubmed Central PMCID: PMC6191029. Epub 2016/11/07. eng).PubMed
11.
go back to reference Parkes A, Clifton K, Al-Awadhi A, Oke O, Warneke CL, Litton JK, et al. Characterization of bone only Metastasis patients with respect to Tumor subtypes. NPJ Breast cancer. 2018;4:2 (PubMed PMID: 29387785. Pubmed Central PMCID: PMC5785511. Epub 2018/02/02. eng).PubMedPubMedCentral Parkes A, Clifton K, Al-Awadhi A, Oke O, Warneke CL, Litton JK, et al. Characterization of bone only Metastasis patients with respect to Tumor subtypes. NPJ Breast cancer. 2018;4:2 (PubMed PMID: 29387785. Pubmed Central PMCID: PMC5785511. Epub 2018/02/02. eng).PubMedPubMedCentral
12.
go back to reference O’Carrigan B, Wong MH, Willson ML, Stockler MR, Pavlakis N, Goodwin A. Bisphosphonates and other bone agents for Breast cancer. Cochrane Database Syst Rev. 2017;10(10):Cd003474 (PubMed PMID: 29082518. Pubmed Central PMCID: PMC6485886 AG: none known. Epub 2017/10/31. eng).PubMed O’Carrigan B, Wong MH, Willson ML, Stockler MR, Pavlakis N, Goodwin A. Bisphosphonates and other bone agents for Breast cancer. Cochrane Database Syst Rev. 2017;10(10):Cd003474 (PubMed PMID: 29082518. Pubmed Central PMCID: PMC6485886 AG: none known. Epub 2017/10/31. eng).PubMed
13.
go back to reference Fang J, Xu Q. Differences of osteoblastic bone metastases and osteolytic bone metastases in clinical features and molecular characteristics. Clinical & translational oncology: official publication of the Federation of. Span Oncol Soc Natl Cancer Inst Mexico. 2015;17(3):173–9 (PubMed PMID: 25351174. Epub 2014/10/30. eng). Fang J, Xu Q. Differences of osteoblastic bone metastases and osteolytic bone metastases in clinical features and molecular characteristics. Clinical & translational oncology: official publication of the Federation of. Span Oncol Soc Natl Cancer Inst Mexico. 2015;17(3):173–9 (PubMed PMID: 25351174. Epub 2014/10/30. eng).
14.
go back to reference Kuchuk I, Hutton B, Moretto P, Ng T, Addison CL, Clemons M. Incidence, consequences and treatment of bone metastases in Breast cancer patients-experience from a single cancer centre. J bone Oncol. 2013;2(4):137–44 (PubMed PMID: 26909284. Pubmed Central PMCID: PMC4723382. Epub 2013/12/01. eng).PubMedPubMedCentral Kuchuk I, Hutton B, Moretto P, Ng T, Addison CL, Clemons M. Incidence, consequences and treatment of bone metastases in Breast cancer patients-experience from a single cancer centre. J bone Oncol. 2013;2(4):137–44 (PubMed PMID: 26909284. Pubmed Central PMCID: PMC4723382. Epub 2013/12/01. eng).PubMedPubMedCentral
15.
go back to reference Lee SJ, Park S, Ahn HK, Yi JH, Cho EY, Sun JM, et al. Implications of bone-only metastases in Breast cancer: favorable preference with excellent outcomes of hormone receptor positive Breast cancer. Cancer Res Treat. 2011;43(2):89–95 (PubMed PMID: 21811424. Pubmed Central PMCID: PMC3138922. Epub 2011/08/04. eng).PubMedPubMedCentral Lee SJ, Park S, Ahn HK, Yi JH, Cho EY, Sun JM, et al. Implications of bone-only metastases in Breast cancer: favorable preference with excellent outcomes of hormone receptor positive Breast cancer. Cancer Res Treat. 2011;43(2):89–95 (PubMed PMID: 21811424. Pubmed Central PMCID: PMC3138922. Epub 2011/08/04. eng).PubMedPubMedCentral
16.
go back to reference Thanopoulou E, Khader L, Caira M, Wardley A, Ettl J, Miglietta F, et al. Therapeutic strategies for the management of hormone Receptor-Positive, human epidermal growth factor receptor 2-Positive (HR+/HER2+) Breast Cancer: a review of the current literature. Cancers. 2020;12(11): 3317 (PubMed PMID: 33182657. Pubmed Central PMCID: PMC7696181. Epub 2020/11/14. eng).PubMedPubMedCentral Thanopoulou E, Khader L, Caira M, Wardley A, Ettl J, Miglietta F, et al. Therapeutic strategies for the management of hormone Receptor-Positive, human epidermal growth factor receptor 2-Positive (HR+/HER2+) Breast Cancer: a review of the current literature. Cancers. 2020;12(11): 3317 (PubMed PMID: 33182657. Pubmed Central PMCID: PMC7696181. Epub 2020/11/14. eng).PubMedPubMedCentral
17.
go back to reference Invernizzi M, Kim J, Fusco N. Editorial. Quality of life in Breast Cancer patients and survivors. Front Oncol. 2020;10.PubMedPubMedCentral Invernizzi M, Kim J, Fusco N. Editorial. Quality of life in Breast Cancer patients and survivors. Front Oncol. 2020;10.PubMedPubMedCentral
18.
go back to reference Baek YH, Jeon HL, Oh IS, Yang H, Park J, Shin JY. Incidence of skeletal-related events in patients with breast or prostate cancer-induced bone Metastasis or Multiple Myeloma: a 12-year longitudinal nationwide healthcare database study. Cancer Epidemiol. 2019;61:104–10 (PubMed PMID: 31176960. Epub 2019/06/10. eng).PubMed Baek YH, Jeon HL, Oh IS, Yang H, Park J, Shin JY. Incidence of skeletal-related events in patients with breast or prostate cancer-induced bone Metastasis or Multiple Myeloma: a 12-year longitudinal nationwide healthcare database study. Cancer Epidemiol. 2019;61:104–10 (PubMed PMID: 31176960. Epub 2019/06/10. eng).PubMed
19.
go back to reference D’Oronzo S, Wood S, Brown JE. The use of bisphosphonates to treat skeletal Complications in solid tumours. Bone. 2021;147:115907 (PubMed PMID: 33676057. Epub 2021/03/07. eng).PubMed D’Oronzo S, Wood S, Brown JE. The use of bisphosphonates to treat skeletal Complications in solid tumours. Bone. 2021;147:115907 (PubMed PMID: 33676057. Epub 2021/03/07. eng).PubMed
20.
go back to reference Guise TA. Breast cancer bone metastases: it’s all about the neighborhood. Cell. 2013;154(5):957–9 (PubMed PMID: 23993088. Epub 2013/09/03. eng).PubMed Guise TA. Breast cancer bone metastases: it’s all about the neighborhood. Cell. 2013;154(5):957–9 (PubMed PMID: 23993088. Epub 2013/09/03. eng).PubMed
21.
go back to reference Invernizzi M, Venetis K, Sajjadi E, Piciotti R, de Sire A, Fusco N. Understanding the biology of volumetric muscle loss for an individualized exercise rehabilitation approach in Breast cancer patients. Curr Opin Pharmacol. 2021;58:27–34 (PubMed PMID: 33848933. Epub 2021/04/14. eng).PubMed Invernizzi M, Venetis K, Sajjadi E, Piciotti R, de Sire A, Fusco N. Understanding the biology of volumetric muscle loss for an individualized exercise rehabilitation approach in Breast cancer patients. Curr Opin Pharmacol. 2021;58:27–34 (PubMed PMID: 33848933. Epub 2021/04/14. eng).PubMed
22.
go back to reference Invernizzi M, de Sire A, Fusco N. Rethinking the clinical management of volumetric muscle loss in patients with spinal cord injury: synergy among nutritional supplementation, pharmacotherapy, and rehabilitation. Curr Opin Pharmacol. 2021;57:132–9 (PubMed PMID: 33721616. Epub 2021/03/16. eng).PubMed Invernizzi M, de Sire A, Fusco N. Rethinking the clinical management of volumetric muscle loss in patients with spinal cord injury: synergy among nutritional supplementation, pharmacotherapy, and rehabilitation. Curr Opin Pharmacol. 2021;57:132–9 (PubMed PMID: 33721616. Epub 2021/03/16. eng).PubMed
23.
go back to reference Aran D, Hu Z, Butte AJ. xCell: digitally portraying the tissue cellular heterogeneity landscape. Genome biology. 2017;18(1):220. PubMed PMID: 29141660. Pubmed Central PMCID: PMC5688663 The authors declare that they have no competing interests. PUBLISHER’S NOTE: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Epub 2017/11/17. eng.PubMedPubMedCentral Aran D, Hu Z, Butte AJ. xCell: digitally portraying the tissue cellular heterogeneity landscape. Genome biology. 2017;18(1):220. PubMed PMID: 29141660. Pubmed Central PMCID: PMC5688663 The authors declare that they have no competing interests. PUBLISHER’S NOTE: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Epub 2017/11/17. eng.PubMedPubMedCentral
24.
go back to reference Hänzelmann S, Castelo R, Guinney J. BMC Bioinformatics. 2013;14: 7 (PubMed PMID: 23323831. Pubmed Central PMCID: PMC3618321. Epub 2013/01/18. eng. GSVA: gene set variation analysis for microarray and RNA-seq data).PubMedPubMedCentral Hänzelmann S, Castelo R, Guinney J. BMC Bioinformatics. 2013;14: 7 (PubMed PMID: 23323831. Pubmed Central PMCID: PMC3618321. Epub 2013/01/18. eng. GSVA: gene set variation analysis for microarray and RNA-seq data).PubMedPubMedCentral
25.
go back to reference Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. Proc Natl Acad Sci USA. 2005;102(43):15545–50 (PubMed PMID: 16199517. Pubmed Central PMCID: PMC1239896. Epub 2005/10/04. eng. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles).PubMedPubMedCentral Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. Proc Natl Acad Sci USA. 2005;102(43):15545–50 (PubMed PMID: 16199517. Pubmed Central PMCID: PMC1239896. Epub 2005/10/04. eng. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles).PubMedPubMedCentral
26.
go back to reference Yu G, Wang LG, Han Y, He QY. clusterProfiler: an R package for comparing biological themes among gene clusters. OMICS. 2012;16(5):284–7 (PubMed PMID: 22455463. Pubmed Central PMCID: PMC3339379. Epub 2012/03/30. eng).PubMedPubMedCentral Yu G, Wang LG, Han Y, He QY. clusterProfiler: an R package for comparing biological themes among gene clusters. OMICS. 2012;16(5):284–7 (PubMed PMID: 22455463. Pubmed Central PMCID: PMC3339379. Epub 2012/03/30. eng).PubMedPubMedCentral
27.
go back to reference Colwill K, Gräslund S. A roadmap to generate renewable protein binders to the human proteome. Nat Methods. 2011;8(7):551–8 (PubMed PMID: 21572409. Epub 2011/05/17. eng).PubMed Colwill K, Gräslund S. A roadmap to generate renewable protein binders to the human proteome. Nat Methods. 2011;8(7):551–8 (PubMed PMID: 21572409. Epub 2011/05/17. eng).PubMed
28.
go back to reference Ren X, Chen X, Ji Y, Li L, Li Y, Qin C, et al. Upregulation of KIF20A promotes Tumor proliferation and invasion in renal clear cell carcinoma and is associated with adverse clinical outcome. Aging. 2020;12(24):25878–94 (PubMed PMID: 33232285. Pubmed Central PMCID: PMC7803492. Epub 2020/11/25. eng).PubMedPubMedCentral Ren X, Chen X, Ji Y, Li L, Li Y, Qin C, et al. Upregulation of KIF20A promotes Tumor proliferation and invasion in renal clear cell carcinoma and is associated with adverse clinical outcome. Aging. 2020;12(24):25878–94 (PubMed PMID: 33232285. Pubmed Central PMCID: PMC7803492. Epub 2020/11/25. eng).PubMedPubMedCentral
29.
go back to reference Fu A, Yu Z, Zhang E, Song J. Long noncoding RNA ZBED3-AS1 restrains Breast cancer progression by targeting the microRNA-513a-5p/KLF6 axis. Thorac cancer. 2021;12(20):2719–31 (PubMed PMID: 34427978. Pubmed Central PMCID: PMC8520814. Epub 2021/08/25. eng).PubMedPubMedCentral Fu A, Yu Z, Zhang E, Song J. Long noncoding RNA ZBED3-AS1 restrains Breast cancer progression by targeting the microRNA-513a-5p/KLF6 axis. Thorac cancer. 2021;12(20):2719–31 (PubMed PMID: 34427978. Pubmed Central PMCID: PMC8520814. Epub 2021/08/25. eng).PubMedPubMedCentral
30.
go back to reference Jatoi I, Miller AB. Why is Breast-cancer mortality declining? Lancet Oncol. 2003;4(4):251–4 (PubMed PMID: 12681269. Epub 2003/04/12. eng).PubMed Jatoi I, Miller AB. Why is Breast-cancer mortality declining? Lancet Oncol. 2003;4(4):251–4 (PubMed PMID: 12681269. Epub 2003/04/12. eng).PubMed
31.
go back to reference Coughlin SS. Epidemiology of Breast Cancer in women. Advances in experimental medicine and biology. 2019;1152:9–29 PubMed PMID: 31456177. Epub 2019/08/29. eng.PubMed Coughlin SS. Epidemiology of Breast Cancer in women. Advances in experimental medicine and biology. 2019;1152:9–29 PubMed PMID: 31456177. Epub 2019/08/29. eng.PubMed
32.
go back to reference Emens LA. Breast Cancer Immunotherapy: Facts and Hopes. Clinical cancer research: an official journal of the American Association for. Can Res. 2018;24(3):511–20 (PubMed PMID: 28801472. Pubmed Central PMCID: PMC5796849. Epub 2017/08/13. eng). Emens LA. Breast Cancer Immunotherapy: Facts and Hopes. Clinical cancer research: an official journal of the American Association for. Can Res. 2018;24(3):511–20 (PubMed PMID: 28801472. Pubmed Central PMCID: PMC5796849. Epub 2017/08/13. eng).
33.
go back to reference Lahiri A, Maji A, Potdar PD, Singh N, Parikh P, Bisht B, et al. Lung cancer immunotherapy: progress, pitfalls, and promises. Mol Cancer. 2023;22(1):40 (PubMed PMID: 36810079. Pubmed Central PMCID: PMC9942077. Epub 2023/02/23. eng).PubMedPubMedCentral Lahiri A, Maji A, Potdar PD, Singh N, Parikh P, Bisht B, et al. Lung cancer immunotherapy: progress, pitfalls, and promises. Mol Cancer. 2023;22(1):40 (PubMed PMID: 36810079. Pubmed Central PMCID: PMC9942077. Epub 2023/02/23. eng).PubMedPubMedCentral
34.
go back to reference Tivol EA, Borriello F, Schweitzer AN, Lynch WP, Bluestone JA, Sharpe AH. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity. 1995;3(5):541–7 (PubMed PMID: 7584144. Epub 1995/11/01. eng).PubMed Tivol EA, Borriello F, Schweitzer AN, Lynch WP, Bluestone JA, Sharpe AH. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity. 1995;3(5):541–7 (PubMed PMID: 7584144. Epub 1995/11/01. eng).PubMed
35.
go back to reference Keir ME, Francisco LM, Sharpe AH. PD-1 and its ligands in T-cell immunity. Curr Opin Immunol. 2007;19(3):309–14 (PubMed PMID: 17433872. Epub 2007/04/17. eng).PubMed Keir ME, Francisco LM, Sharpe AH. PD-1 and its ligands in T-cell immunity. Curr Opin Immunol. 2007;19(3):309–14 (PubMed PMID: 17433872. Epub 2007/04/17. eng).PubMed
36.
go back to reference Vranic S, Cyprian FS, Gatalica Z, Palazzo J. PD-L1 status in Breast cancer: current view and perspectives. Sem Cancer Biol. 2021;72:146–54 (PubMed PMID: 31883913. Epub 2019/12/31. eng). Vranic S, Cyprian FS, Gatalica Z, Palazzo J. PD-L1 status in Breast cancer: current view and perspectives. Sem Cancer Biol. 2021;72:146–54 (PubMed PMID: 31883913. Epub 2019/12/31. eng).
37.
go back to reference Narod SA, Salmena L. BRCA1 and BRCA2 mutations and Breast cancer. Discov Med. 2011;12(66):445–53 (PubMed PMID: 22127115. Epub 2011/12/01. eng).PubMed Narod SA, Salmena L. BRCA1 and BRCA2 mutations and Breast cancer. Discov Med. 2011;12(66):445–53 (PubMed PMID: 22127115. Epub 2011/12/01. eng).PubMed
38.
go back to reference Baretta Z, Mocellin S, Goldin E, Olopade OI, Huo D. Effect of BRCA germline mutations on Breast cancer prognosis: a systematic review and meta-analysis. Medicine. 2016;95(40): e4975 (PubMed PMID: 27749552. Pubmed Central PMCID: PMC5059054. Epub 2016/10/18. eng).PubMedPubMedCentral Baretta Z, Mocellin S, Goldin E, Olopade OI, Huo D. Effect of BRCA germline mutations on Breast cancer prognosis: a systematic review and meta-analysis. Medicine. 2016;95(40): e4975 (PubMed PMID: 27749552. Pubmed Central PMCID: PMC5059054. Epub 2016/10/18. eng).PubMedPubMedCentral
39.
go back to reference Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Cancer J Clin. 2018;68(6):394–424 (PubMed PMID: 30207593. Epub 2018/09/13. eng). Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Cancer J Clin. 2018;68(6):394–424 (PubMed PMID: 30207593. Epub 2018/09/13. eng).
40.
go back to reference Riggio AI, Varley KE, Welm AL. The lingering mysteries of metastatic recurrence in Breast cancer. Br J Cancer. 2021;124(1):13–26 (PubMed PMID: 33239679. Pubmed Central PMCID: PMC7782773. Epub 2020/11/27. eng).PubMed Riggio AI, Varley KE, Welm AL. The lingering mysteries of metastatic recurrence in Breast cancer. Br J Cancer. 2021;124(1):13–26 (PubMed PMID: 33239679. Pubmed Central PMCID: PMC7782773. Epub 2020/11/27. eng).PubMed
41.
go back to reference Coleman RE, Croucher PI, Padhani AR, Clézardin P, Chow E, Fallon M, et al. Bone metastases. Nat Reviews Disease Primers. 2020;6(1):83 (PubMed PMID: 33060614. Epub 2020/10/17. eng).PubMed Coleman RE, Croucher PI, Padhani AR, Clézardin P, Chow E, Fallon M, et al. Bone metastases. Nat Reviews Disease Primers. 2020;6(1):83 (PubMed PMID: 33060614. Epub 2020/10/17. eng).PubMed
42.
go back to reference Haider MT, Smit DJ, Taipaleenmäki H. The endosteal niche in Breast Cancer bone Metastasis. Front Oncol. 2020;10: 335 (PubMed PMID: 32232008. Pubmed Central PMCID: PMC7082928. Epub 2020/04/02. eng).PubMedPubMedCentral Haider MT, Smit DJ, Taipaleenmäki H. The endosteal niche in Breast Cancer bone Metastasis. Front Oncol. 2020;10: 335 (PubMed PMID: 32232008. Pubmed Central PMCID: PMC7082928. Epub 2020/04/02. eng).PubMedPubMedCentral
43.
go back to reference Zarrer J, Haider MT, Smit DJ, Taipaleenmäki H. Pathological crosstalk between metastatic Breast Cancer cells and the bone microenvironment. Biomolecules. 2020;10(2): 337 (PubMed PMID: 32092997. Pubmed Central PMCID: PMC7072692. Epub 2020/02/26. eng).PubMedPubMedCentral Zarrer J, Haider MT, Smit DJ, Taipaleenmäki H. Pathological crosstalk between metastatic Breast Cancer cells and the bone microenvironment. Biomolecules. 2020;10(2): 337 (PubMed PMID: 32092997. Pubmed Central PMCID: PMC7072692. Epub 2020/02/26. eng).PubMedPubMedCentral
44.
go back to reference Monteiro AC, Leal AC, Gonçalves-Silva T, Mercadante AC, Kestelman F, Chaves SB, et al. T cells induce pre-metastatic osteolytic Disease and help bone metastases establishment in a mouse model of metastatic Breast cancer. PLoS ONE. 2013;8(7):e68171. PubMed PMID: 23935856. Pubmed Central PMCID: PMC3730734. Epub 2013/08/13. eng.PubMedPubMedCentral Monteiro AC, Leal AC, Gonçalves-Silva T, Mercadante AC, Kestelman F, Chaves SB, et al. T cells induce pre-metastatic osteolytic Disease and help bone metastases establishment in a mouse model of metastatic Breast cancer. PLoS ONE. 2013;8(7):e68171. PubMed PMID: 23935856. Pubmed Central PMCID: PMC3730734. Epub 2013/08/13. eng.PubMedPubMedCentral
45.
go back to reference Brook N, Brook E, Dharmarajan A, Dass CR, Chan A. Breast cancer bone metastases: pathogenesis and therapeutic targets. Int J Biochem Cell Biol. 2018;96:63–78 (PubMed PMID: 29309917. Epub 2018/01/09. eng).PubMed Brook N, Brook E, Dharmarajan A, Dass CR, Chan A. Breast cancer bone metastases: pathogenesis and therapeutic targets. Int J Biochem Cell Biol. 2018;96:63–78 (PubMed PMID: 29309917. Epub 2018/01/09. eng).PubMed
46.
go back to reference Fornetti J, Welm AL, Stewart SA. Understanding the bone in Cancer Metastasis. Journal of bone and mineral research: the official journal of the American Society for Bone and Mineral. Research. 2018;33(12):2099–113 (PubMed PMID: 30476357. Epub 2018/11/27. eng). Fornetti J, Welm AL, Stewart SA. Understanding the bone in Cancer Metastasis. Journal of bone and mineral research: the official journal of the American Society for Bone and Mineral. Research. 2018;33(12):2099–113 (PubMed PMID: 30476357. Epub 2018/11/27. eng).
47.
go back to reference Liang Y, Zhang H, Song X, Yang Q. Metastatic heterogeneity of Breast cancer: molecular mechanism and potential therapeutic targets. Sem Cancer Biol. 2020;60:14–27 (PubMed PMID: 31421262. Epub 2019/08/20. eng). Liang Y, Zhang H, Song X, Yang Q. Metastatic heterogeneity of Breast cancer: molecular mechanism and potential therapeutic targets. Sem Cancer Biol. 2020;60:14–27 (PubMed PMID: 31421262. Epub 2019/08/20. eng).
48.
go back to reference Yin Z, Wu D, Shi J, Wei X, Jin N, Lu X, et al. Identification of ALDH3A2 as a novel prognostic biomarker in gastric adenocarcinoma using integrated bioinformatics analysis. BMC Cancer. 2020;20(1):1062 (PubMed PMID: 33148208. Pubmed Central PMCID: PMC7640415. Epub 2020/11/06. eng).PubMedPubMedCentral Yin Z, Wu D, Shi J, Wei X, Jin N, Lu X, et al. Identification of ALDH3A2 as a novel prognostic biomarker in gastric adenocarcinoma using integrated bioinformatics analysis. BMC Cancer. 2020;20(1):1062 (PubMed PMID: 33148208. Pubmed Central PMCID: PMC7640415. Epub 2020/11/06. eng).PubMedPubMedCentral
49.
go back to reference Wei Y, Chen X, Ren X, Wang B, Zhang Q, Bu H, et al. Identification of MX2 as a Novel Prognostic Biomarker for Sunitinib Resistance in Clear Cell Renal Cell Carcinoma. Front Genet. 2021;12: 680369 (PubMed PMID: 34306023. Pubmed Central PMCID: PMC8299280. Epub 2021/07/27. eng).PubMedPubMedCentral Wei Y, Chen X, Ren X, Wang B, Zhang Q, Bu H, et al. Identification of MX2 as a Novel Prognostic Biomarker for Sunitinib Resistance in Clear Cell Renal Cell Carcinoma. Front Genet. 2021;12: 680369 (PubMed PMID: 34306023. Pubmed Central PMCID: PMC8299280. Epub 2021/07/27. eng).PubMedPubMedCentral
50.
go back to reference Holtsträter C, Schrörs B, Bukur T, Löwer M. Bioinformatics for Cancer Immunotherapy. Methods in molecular biology. (Clifton NJ). 2020;2120:1–9 (PubMed PMID: 32124308. Epub 2020/03/04. eng). Holtsträter C, Schrörs B, Bukur T, Löwer M. Bioinformatics for Cancer Immunotherapy. Methods in molecular biology. (Clifton NJ). 2020;2120:1–9 (PubMed PMID: 32124308. Epub 2020/03/04. eng).
51.
go back to reference Hu JL, Wang W, Lan XL, Zeng ZC, Liang YS, Yan YR, et al. CAFs secreted exosomes promote Metastasis and chemotherapy resistance by enhancing cell stemness and epithelial-mesenchymal transition in Colorectal cancer. Mol Cancer. 2019;18(1):91 (PubMed PMID: 31064356. Pubmed Central PMCID: PMC6503554. Epub 2019/05/09. eng).PubMedPubMedCentral Hu JL, Wang W, Lan XL, Zeng ZC, Liang YS, Yan YR, et al. CAFs secreted exosomes promote Metastasis and chemotherapy resistance by enhancing cell stemness and epithelial-mesenchymal transition in Colorectal cancer. Mol Cancer. 2019;18(1):91 (PubMed PMID: 31064356. Pubmed Central PMCID: PMC6503554. Epub 2019/05/09. eng).PubMedPubMedCentral
52.
go back to reference Kashima H, Noma K, Ohara T, Kato T, Katsura Y, Komoto S, et al. Cancer-associated fibroblasts (CAFs) promote the lymph node Metastasis of esophageal squamous cell carcinoma. Int J Cancer. 2019;144(4):828–40 (PubMed PMID: 30367467. Epub 2018/10/28. eng).PubMed Kashima H, Noma K, Ohara T, Kato T, Katsura Y, Komoto S, et al. Cancer-associated fibroblasts (CAFs) promote the lymph node Metastasis of esophageal squamous cell carcinoma. Int J Cancer. 2019;144(4):828–40 (PubMed PMID: 30367467. Epub 2018/10/28. eng).PubMed
53.
go back to reference Wen S, Hou Y, Fu L, Xi L, Yang D, Zhao M, et al. Cancer-associated fibroblast (CAF)-derived IL32 promotes Breast cancer cell invasion and Metastasis via integrin β3-p38 MAPK signalling. Cancer Lett. 2019;442:320–32 (PubMed PMID: 30391782. Epub 2018/11/06. eng).PubMed Wen S, Hou Y, Fu L, Xi L, Yang D, Zhao M, et al. Cancer-associated fibroblast (CAF)-derived IL32 promotes Breast cancer cell invasion and Metastasis via integrin β3-p38 MAPK signalling. Cancer Lett. 2019;442:320–32 (PubMed PMID: 30391782. Epub 2018/11/06. eng).PubMed
54.
go back to reference Zheng S, Zou Y, Tang Y, Yang A, Liang JY, Wu L, et al. Landscape of cancer-associated fibroblasts identifies the secreted biglycan as a protumor and immunosuppressive factor in triple-negative Breast cancer. Oncoimmunology. 2022;11(1): 2020984 (PubMed PMID: 35003899. Pubmed Central PMCID: PMC8741292. Epub 2022/01/11. eng).PubMedPubMedCentral Zheng S, Zou Y, Tang Y, Yang A, Liang JY, Wu L, et al. Landscape of cancer-associated fibroblasts identifies the secreted biglycan as a protumor and immunosuppressive factor in triple-negative Breast cancer. Oncoimmunology. 2022;11(1): 2020984 (PubMed PMID: 35003899. Pubmed Central PMCID: PMC8741292. Epub 2022/01/11. eng).PubMedPubMedCentral
55.
go back to reference Gobin E, Bagwell K, Wagner J, Mysona D, Sandirasegarane S, Smith N, et al. A pan-cancer perspective of matrix metalloproteases (MMP) gene expression profile and their diagnostic/prognostic potential. BMC Cancer. 2019;19(1):581 (PubMed PMID: 31200666. Pubmed Central PMCID: PMC6567474. Epub 2019/06/16. eng).PubMedPubMedCentral Gobin E, Bagwell K, Wagner J, Mysona D, Sandirasegarane S, Smith N, et al. A pan-cancer perspective of matrix metalloproteases (MMP) gene expression profile and their diagnostic/prognostic potential. BMC Cancer. 2019;19(1):581 (PubMed PMID: 31200666. Pubmed Central PMCID: PMC6567474. Epub 2019/06/16. eng).PubMedPubMedCentral
56.
go back to reference Zhang H, Yang Q, Lian X, Jiang P, Cui J. Hypoxia-inducible Factor-1α (HIF-1α) promotes Hypoxia-Induced Invasion and Metastasis in Ovarian Cancer by Targeting Matrix Metallopeptidase 13 (MMP13). Medical science monitor: international medical journal of experimental and clinical research. 2019;25:7202–8 PubMed PMID: 31587013. Pubmed Central PMCID: PMC6777377. Epub 2019/10/07. eng.PubMed Zhang H, Yang Q, Lian X, Jiang P, Cui J. Hypoxia-inducible Factor-1α (HIF-1α) promotes Hypoxia-Induced Invasion and Metastasis in Ovarian Cancer by Targeting Matrix Metallopeptidase 13 (MMP13). Medical science monitor: international medical journal of experimental and clinical research. 2019;25:7202–8 PubMed PMID: 31587013. Pubmed Central PMCID: PMC6777377. Epub 2019/10/07. eng.PubMed
57.
go back to reference Kumamoto K, Fujita K, Kurotani R, Saito M, Unoki M, Hagiwara N, et al. ING2 is upregulated in colon Cancer and increases invasion by enhanced MMP13 expression. Int J Cancer. 2009;125(6):1306–15 (PubMed PMID: 19437536. Pubmed Central PMCID: PMC2790157. Epub 2009/05/14. eng).PubMedPubMedCentral Kumamoto K, Fujita K, Kurotani R, Saito M, Unoki M, Hagiwara N, et al. ING2 is upregulated in colon Cancer and increases invasion by enhanced MMP13 expression. Int J Cancer. 2009;125(6):1306–15 (PubMed PMID: 19437536. Pubmed Central PMCID: PMC2790157. Epub 2009/05/14. eng).PubMedPubMedCentral
58.
go back to reference Ma Y, Cang S, Li G, Su Y, Zhang H, Wang L, et al. Integrated analysis of transcriptome data revealed MMP3 and MMP13 as critical genes in anaplastic thyroid cancer progression. J Cell Physiol. 2019;234(12):22260–71 (PubMed PMID: 31081124. Epub 2019/05/14. eng).PubMed Ma Y, Cang S, Li G, Su Y, Zhang H, Wang L, et al. Integrated analysis of transcriptome data revealed MMP3 and MMP13 as critical genes in anaplastic thyroid cancer progression. J Cell Physiol. 2019;234(12):22260–71 (PubMed PMID: 31081124. Epub 2019/05/14. eng).PubMed
59.
go back to reference Luchian I, Goriuc A, Sandu D, Covasa M. The role of Matrix metalloproteinases (MMP-8, MMP-9, MMP-13) in Periodontal and Peri-implant pathological processes. Int J Mol Sci. 2022;23(3): 1806 (PubMed PMID: 35163727. Pubmed Central PMCID: PMC8837018. Epub 2022/02/16. eng).PubMedPubMedCentral Luchian I, Goriuc A, Sandu D, Covasa M. The role of Matrix metalloproteinases (MMP-8, MMP-9, MMP-13) in Periodontal and Peri-implant pathological processes. Int J Mol Sci. 2022;23(3): 1806 (PubMed PMID: 35163727. Pubmed Central PMCID: PMC8837018. Epub 2022/02/16. eng).PubMedPubMedCentral
60.
go back to reference Zhou Y, Hu Z, Li N, Jiang R. Interleukin-32 stimulates osteosarcoma cell invasion and motility via AKT pathway-mediated MMP-13 expression. Int J Mol Med. 2015;35(6):1729–33 (PubMed PMID: 25846944. Epub 2015/04/08. eng).PubMed Zhou Y, Hu Z, Li N, Jiang R. Interleukin-32 stimulates osteosarcoma cell invasion and motility via AKT pathway-mediated MMP-13 expression. Int J Mol Med. 2015;35(6):1729–33 (PubMed PMID: 25846944. Epub 2015/04/08. eng).PubMed
Metadata
Title
Multidimensional analysis to elucidate the possible mechanism of bone metastasis in breast cancer
Authors
Kang Yao
Zhu Xiaojun
Zhao Tingxiao
Liao Shiyao
Ji Lichen
Zhang Wei
Li Yanlei
Tian Jinlong
Ding Xiaoyan
Zhang Jun
Bi Qing
Lv Jun
Publication date
01-12-2023
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2023
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-023-11588-6

Other articles of this Issue 1/2023

BMC Cancer 1/2023 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine